Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Haematologica|September 21, 2023
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairmentSurbhi Sidana, Lauren C Peres, Hamza Hashmi, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Blood Cancer Journal|August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapyChristopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
The New England Journal of Medicine|December 8, 2025
Dual Targeting of Extramedullary Myeloma with Talquetamab and TeclistamabShaji Kumar, María-Victoria Mateos, Jing Christine Ye, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Blood|October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood Advances|August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell LeukemiaGliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances|April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal ImpairmentDanai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple MyelomaDoris K Hansen, Lauren C Peres, Danai Dima, et al.
Pageof 9